english.prescrire.org > Prescrire International > N°247 - April 2023

n°247

April 2023

Issue Contents
Editorial

Free  Order of magnitude

p.87

Marketing Authorisations


Odevixibat (Bylvay°) in progressive familial intrahepatic cholestasis.

p.89-90
Less pruritus, but only short-term follow-up

Lenvatinib (Kisplyx°) + pembrolizumab (Keytruda°) as first-line treatment for advanced renal cancer

p.91

Abrocitinib (Cibinqo°) in atopic eczema

p.92-93

Editors' opinion. Indissociable

p.93

Upadacitinib (Rinvoq°) in atopic eczema

p.93

Omicron variant BQ.1.1: nirmatrelvir + ritonavir retains activity, monoclonal antibodies do not

p.94-95

Sofosbuvir + velpatasvir (Epclusa°) in chronic hepatitis C from 3 years of age

p.95

Belimumab (Benlysta°) in lupus nephritis

p.96

Risankizumab (Skyrizi°) in psoriatic arthritis

p.97

Fedratinib (Inrebic°) in myelofibrosis

p.97

Eszopiclone (Noxiben°) in insomnia

p.98

Free  Prescrire's ratings of new drugs in 2022: a brief review

p.99-101

Adverse Effects


Paracetamol, pregnancy and urogenital endocrine disruption: inconclusive studies

p.102-103

Olanzapine, quetiapine: abuse

p.104

Ibrutinib: increased risk of sudden death

p.104-105

Melatonin poisoning in children: sometimes serious

p.105

Iodinated contrast media: hypothyroidism in young children

p.106

Tranexamic acid in menorrhagia: thrombosis and embolism

p.106

Known allergy to chlorhexidine: a preventable death

p.107

Common stem: -clone, -pidem

p.107

Outlook


Queries and comments. Retraction of a published article: what are the consequences for evaluation data?

p.108-110

Cancer treatments: what about quality of life?

p.110-111

EMA: clinical data from marketing authorisation procedures published several months late

p.111

Masthead


Free  Masthead

p.86

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe